The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety.

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG / Waubant, E., Banwell, B., Wassmer, E., Sormani, M., Amato, M., Hintzen, R., Krupp, L., Rostásy, K., Tenembaum, S., Chitnis, T.. - In: NEUROLOGY. - ISSN 0028-3878. - ELETTRONICO. - (2019), pp. 1-12. [10.1212/WNL.0000000000007572]

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG

Amato, Maria-Pia;
2019

Abstract

The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety.
2019
1
12
Goal 3: Good health and well-being for people
Waubant, Emmanuelle; Banwell, Brenda; Wassmer, Evangeline; Sormani, Maria-Pia; Amato, Maria-Pia; Hintzen, Rogier; Krupp, Lauren; Rostásy, Kevin; Tenem...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1155433
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 65
  • ???jsp.display-item.citation.isi??? 58
social impact